Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Martijn Intven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5068-5517; OpenAlex author ID A5021970576, A5061843498. Sources: ClinicalTrials.gov.

Their work

Papers
38 (first author 0, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
101
Papers, trials and grants by year

2018: 4 papers · 2019: 1 paper · 2020: none · 2021: 3 papers, 1 trial · 2022: 6 papers · 2023: 4 papers · 2024: 7 papers, 1 trial · 2025: 7 papers · 2026: 6 papers

Papers 38

  1. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  2. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  5. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  6. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  9. Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Th… Co-author DOI 10.1016/j.ijrobp.2025.03.046↗
  10. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  11. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  12. The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells14090632↗
  13. Quantification of Signal Transduction Pathway Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms262311385↗
  14. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  15. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  16. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  17. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  18. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  19. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  20. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  21. Outcome of Pancreatic Surgery During the First 6 Years of a Mandatory Audit Within the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000005628↗
  22. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  23. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Last author DOI 10.1186/s13063-022-07036-8↗
  24. [Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands]. Co-author PMID 37994711↗
  25. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  26. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  27. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Co-author DOI 10.1186/s12885-022-10419-4↗
  28. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Last author DOI 10.1186/s13063-022-06829-1↗
  29. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  30. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  31. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Co-author DOI 10.1016/j.ejso.2020.11.145↗
  32. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  33. Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy? Co-author DOI 10.3389/fonc.2021.744161↗
  34. Postoperative surveillance of pancreatic cancer patients. Co-author DOI 10.1016/j.ejso.2019.05.031↗
  35. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1016/j.ejrad.2018.07.010↗
  36. Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2017.11.002↗
  37. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. Co-author DOI 10.1016/j.hpb.2017.11.009↗
  38. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1259/bjr.20170563↗

Trials 2

  1. Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy Principal investigator NCT06272162↗
  2. Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy Principal investigator NCT04881487↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 31 shared papers, 1 shared trial, 2018–2026 · strength 4.71
  2. Lois A. Daamen · 27 shared papers, 1 shared trial, 2018–2026 · strength 4.54
  3. Hjalmar C. van Santvoort · 30 shared papers, 2018–2026 · strength 4.36
  4. Marc G. Besselink · 25 shared papers, 1 shared trial, 2019–2026 · strength 3.95
  5. Bas Groot Koerkamp · 22 shared papers, 1 shared trial, 2019–2026 · strength 3.44
  6. Ignace H. J. T. de Hingh · 20 shared papers, 2021–2026 · strength 3.05
  7. Martijn W.J. Stommel · 20 shared papers, 2019–2026 · strength 3.00
  8. Vincent Erwin de Meijer · 19 shared papers, 2021–2026 · strength 2.92
  9. Bert A. Bonsing · 16 shared papers, 2021–2026 · strength 2.47
  10. Gert J. Meijer · 15 shared papers, 2018–2026 · strength 2.33
  11. Johanna W. Wilmink · 15 shared papers, 2019–2026 · strength 2.29
  12. Robert C. Verdonk · 14 shared papers, 2022–2026 · strength 2.15
  13. Geert Kazemier M · 15 shared papers, 2021–2026 · strength 2.14
  14. Sebastiaan Festen · 14 shared papers, 2021–2026 · strength 2.11
  15. Iris W.J.M. van Goor · 13 shared papers, 2021–2026 · strength 2.07
  16. Vincent P. Groot · 13 shared papers, 2018–2026 · strength 1.76
  17. Vincent B. Nieuwenhuijs · 11 shared papers, 2021–2026 · strength 1.59
  18. Hanne D. Heerkens · 9 shared papers, 1 shared trial, 2018–2026 · strength 1.54
  19. Hanneke W.M. van Laarhoven · 10 shared papers, 2019–2026 · strength 1.48
  20. Geertjan van Tienhoven · 10 shared papers, 2021–2026 · strength 1.46
  21. Anna M E Bruynzeel · 5 shared papers, 2 shared trials, 2021–2026 · strength 1.36
  22. Joost J.M.E. Nuyttens · 7 shared papers, 1 shared trial, 2019–2026 · strength 1.23
  23. Paul C. M. Andel · 7 shared papers, 2024–2026 · strength 1.22
  24. Casper H.J. van Eijck · 7 shared papers, 2022–2026 · strength 1.14
  25. Lodewijk A.A. Brosens · 8 shared papers, 2021–2024 · strength 1.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.